170 related articles for article (PubMed ID: 11864588)
1. Polyglutamine disease: acetyltransferases awry.
Hughes RE
Curr Biol; 2002 Feb; 12(4):R141-3. PubMed ID: 11864588
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
Steffan JS; Bodai L; Pallos J; Poelman M; McCampbell A; Apostol BL; Kazantsev A; Schmidt E; Zhu YZ; Greenwald M; Kurokawa R; Housman DE; Jackson GR; Marsh JL; Thompson LM
Nature; 2001 Oct; 413(6857):739-43. PubMed ID: 11607033
[TBL] [Abstract][Full Text] [Related]
3. Altered protein acetylation in polyglutamine diseases.
Bodai L; Pallos J; Thompson LM; Marsh JL
Curr Med Chem; 2003 Dec; 10(23):2577-87. PubMed ID: 14529472
[TBL] [Abstract][Full Text] [Related]
4. Neurodegeneration. A glutamine-rich trail leads to transcription factors.
Freiman RN; Tjian R
Science; 2002 Jun; 296(5576):2149-50. PubMed ID: 12077389
[No Abstract] [Full Text] [Related]
5. Huntington's disease. Exploiting expression.
Bates GP
Nature; 2001 Oct; 413(6857):691, 693-4. PubMed ID: 11607014
[No Abstract] [Full Text] [Related]
6. Altered acetylation in polyglutamine disease: an opportunity for therapeutic intervention?
Taylor JP; Fischbeck KH
Trends Mol Med; 2002 May; 8(5):195-7. PubMed ID: 12067622
[TBL] [Abstract][Full Text] [Related]
7. Aberrant histone acetylation, altered transcription, and retinal degeneration in a Drosophila model of polyglutamine disease are rescued by CREB-binding protein.
Taylor JP; Taye AA; Campbell C; Kazemi-Esfarjani P; Fischbeck KH; Min KT
Genes Dev; 2003 Jun; 17(12):1463-8. PubMed ID: 12815067
[TBL] [Abstract][Full Text] [Related]
8. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders.
Sánchez I; Mahlke C; Yuan J
Nature; 2003 Jan; 421(6921):373-9. PubMed ID: 12540902
[TBL] [Abstract][Full Text] [Related]
9. [Histone deacetylase inhibitors as therapeutic agents for polyglutamine disorders].
Jiang H; Jia D; Tang B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):52-5. PubMed ID: 20140868
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders.
Butler R; Bates GP
Nat Rev Neurosci; 2006 Oct; 7(10):784-96. PubMed ID: 16988654
[TBL] [Abstract][Full Text] [Related]
11. [Molecular biology of polyglutamine diseases].
Owecki M; Kozubski W
Postepy Hig Med Dosw; 2002; 56(6):779-88. PubMed ID: 12661407
[TBL] [Abstract][Full Text] [Related]
12. Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases.
Krainc D
Arch Neurol; 2010 Apr; 67(4):388-92. PubMed ID: 20385902
[TBL] [Abstract][Full Text] [Related]
13. Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components.
Stenoien DL; Mielke M; Mancini MA
Nat Cell Biol; 2002 Oct; 4(10):806-10. PubMed ID: 12360291
[TBL] [Abstract][Full Text] [Related]
14. The SV40 T antigen modulates CBP histone acetyltransferase activity.
Valls E; de la Cruz X; Martínez-Balbás MA
Nucleic Acids Res; 2003 Jun; 31(12):3114-22. PubMed ID: 12799439
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).
Sadri-Vakili G; Cha JH
Curr Alzheimer Res; 2006 Sep; 3(4):403-8. PubMed ID: 17017871
[TBL] [Abstract][Full Text] [Related]
16. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin.
Jiang H; Poirier MA; Liang Y; Pei Z; Weiskittel CE; Smith WW; DeFranco DB; Ross CA
Neurobiol Dis; 2006 Sep; 23(3):543-51. PubMed ID: 16766198
[TBL] [Abstract][Full Text] [Related]
17. New light on polyglutamine neurodegenerative disorders: interference with transcription.
Néri C
Trends Mol Med; 2001 Jul; 7(7):283-4. PubMed ID: 11425622
[No Abstract] [Full Text] [Related]
18. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation.
Schaffar G; Breuer P; Boteva R; Behrends C; Tzvetkov N; Strippel N; Sakahira H; Siegers K; Hayer-Hartl M; Hartl FU
Mol Cell; 2004 Jul; 15(1):95-105. PubMed ID: 15225551
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors reduce polyglutamine toxicity.
McCampbell A; Taye AA; Whitty L; Penney E; Steffan JS; Fischbeck KH
Proc Natl Acad Sci U S A; 2001 Dec; 98(26):15179-84. PubMed ID: 11742087
[TBL] [Abstract][Full Text] [Related]
20. Regulating histone acetyltransferases and deacetylases.
Legube G; Trouche D
EMBO Rep; 2003 Oct; 4(10):944-7. PubMed ID: 14528264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
